Skip to main content

Advertisement

SpringerLink
Log in

Interferon and chronic myelogenous leukaemia

  • Papers
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Interferon (IFN) is widely employed in the therapy of chronic myelogenous leukaemia because of its ability to exert the antiproliferative activity on leukaemic haematopoietic progenitors and for the expression for IFN-α receptors by peripheral blood leukaemic cell surfaces. There is no difference between recombinant IFN α 2b and α 2a regarding their efficacy in the treatment of Ph-positive CML patients. Either no randomized studies or the randomized ones show a superior effectiveness of IFN given as single agent in the induction treatment to that one of chemotherapy regarding the complete cytogenic response percentage. The ability of IFN-γ to induce the expression of adhesion molecules such LFA 1 and ICAM 1 on peripheral blood leukaemic cell surfaces may suggest its use in the induction therapy of CML patients. Other than, a superior effectiveness of combined therapy including interferon and chemotherapy agents compared to chemotherapy alone has also been found. Finally no large series of trials to study the IFN efficacy both as second line treatment and maintenance therapy have been carried out.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rowley, J.D. (1973) A new consistent chromosomal abnormality in chronic granulocytic leukaemia identified by quinacrine fluorescence and giemsa stainings.Nature 243, 290.

    Article  PubMed  CAS  Google Scholar 

  2. Dreazen, O., Canaani, E. and Gale, R.P. (1988) Molecular biology of chronic myelogenous leukemia.Sem. Hematol. 30, 35.

    Google Scholar 

  3. Talpaz, M., Kantarjian, H., Kurzrock, R. and Gutterman, J. (1988) Therapy of chronic myelogenous leukaemia: chemotherapy and interferons.Sem. Hematol. 30, 62.

    Google Scholar 

  4. Baccarani, M., Ruggero, D., Tura, S. and the Italian Cooperative Study Group on Chronic Myeloid Leukaemia. (1978) Therapy of chronic myeloid leukemia (CML): interim report on protocols CML/73 and CML/74.Boll. Ist. Sierot. Milanese 545, 278.

    Google Scholar 

  5. Kantarjian, H.M., Vellekoop, L., McCredie, K.B. et al. (1985) Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemia.J. Clin. Oncol. 3, 192.

    PubMed  CAS  Google Scholar 

  6. Thomas, E.D.et al. (1986) Marrow transplantation for the treatment of chronic myelogenous leukemia.Ann. Int. Med. 104, 155.

    PubMed  CAS  Google Scholar 

  7. Raefsky, E.L., Platanias, L.C., Zoumbos, N.C.et al. (1985) Studies of interferon as a regulator of hemopoietic cell proliferation.J. Immunol. 135, 2507.

    PubMed  CAS  Google Scholar 

  8. Talpaz, M., Spitzer, G., Hittelman, W., Kantarjian, H. and Gutterman, J.U. (1987) Changes in granulocyte-monocyte colony-forming cells among leukocyte-interferon-treated chronic myelogenous leukaemia patients.Exp. Hematol. 15, 331.

    Google Scholar 

  9. Rosemblum, M.G., Maxwell, B.L., Talpaz, M.et al. (1986)In vivo sensitivity and resistance of chronic myelogenous leukaemia cells to alpha interferon: correlation with receptor binding and induction of 2-5-oligoadenylate synthetase.Cancer Res. 46, 4848.

    Google Scholar 

  10. Tanaka, T. and Craig, A.W. (1970) Cell-free transmission of murine myeloid leukaemia.Eur. J. Cancer 6, 329.

    PubMed  CAS  Google Scholar 

  11. Talpaz, M., McCredie, KB., Mauligit, GM., Gutterman, J.U. (1983) Leukocyte interferon induced myeloid cytoreduction in chronic myelogenous leukaemia.Blood 62, 689.

    PubMed  CAS  Google Scholar 

  12. Talpaz, M., Kantarjian, HM., McCredie, KB. (1986) Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha in chronic myelogenous leukaemia.N. Engl. J. Med. 314, 1065.

    PubMed  CAS  Google Scholar 

  13. Niederle, N., Doberauer, C., Kloke, O. (1986) Treatment of chronic myelogenous leukemia with recombinant interferon alpha (IFN alpha-2b).Proc. Am. Soc. Clin. Oncol. 5, 236.

    Google Scholar 

  14. Alimena, G., Morra, E. and Lazzarino, M. (1988) Interferon alpha-2b as therapy for Ph-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration.Blood 72, 642.

    PubMed  CAS  Google Scholar 

  15. Ozer H., Mick. and Testa, J. (1988) Subcutaneous alpha interferon shows substantial activity in untreated chronic phase Philadelphia chromosome positive chronic myelogenous leukemia.Proc. Am. Soc. Clin. Oncol. 7, 684.

    Google Scholar 

  16. Ozer, H. (1988) Biotherapy of chronic myelogenous leukemia with interferon.Semin. Oncol. 15, 14.

    PubMed  CAS  Google Scholar 

  17. Tura, S., Russo, D., Zuffa, E. and Fiacchini, M. (1990) A prospective comparison of human recombinant interferon alpha-2a and conventional chemotherapy in chronic myeloid leukemia. Interim report of the Italian Study.Blood 76, (suppl. 1) 329a.

  18. Broustet, A., Reifers, J., Marit, G., Fiere, D., Jaubert, J., Reynaud, J., Pris, J., Bernard, P., Charring, C., Zong. Qi Wenn Berteas, M.F., Dastugue, N. and Parlier, Y. (1991) Hydroxyurea versus interferon alpha-2b in chronic myelogenous leukemia: preliminary results of an open French multicentre randomized study.Eur. J. Cancer 27 (4), S18.

  19. Asano, S., Ogura, H., Tani, K., Inoue, T., Tojo, A. and Ozaua, K. (1991) Several new approaches to improvement of alpha interferon therapy in chronic myelogenous leukemia.Eur. J. Cancer 27 (4), S21.

  20. Aitchison, R., McSweeney, E., Butler, L. and Weidemann L. (1991) Cytogenetic and breakpoint cluster region (bcr) changes in chronic myelogenous leukemia treated with low-dose alpha interferon.Eur. J. Cancer 27 (4), S27.

  21. Park, C.W., Han, C.H., Kim, C.C. and Kim, D.J. (1991) Randomized, parallel-group comparison of interferon alpha-2b plus hydroxyurea versus hydroxyurea alone in patients with chronic myelogenous leukemia in chronic phase.Eur. J. Cancer 27 (4), S27.

  22. Grandér, D., Wang, P., Heyman, M. and Einhorn, S. (1992) Effects of IFNS gamma and alpha on cell adhesion and expression of cell adhesion molecules in primary chronic myelogenous leukemia cells.Acta Ann. Meet. I.S.I.R.-Toronto S73.

  23. Kurzrock, R., Talpaz, M. and Kantarjian, H. (1987) Therapy of chronic myelogenous leukemia with recombinant interferon gamma.Blood 70, 943.

    PubMed  CAS  Google Scholar 

  24. Talpaz, M., Kurzrock, R. and Kantarjian, H. (1991) A phase II study of alternating alpha-2a interferon and gamma interferon therapy in patients with chronic myelogenous leukemia.Cancer 68, 2125.

    Article  PubMed  CAS  Google Scholar 

  25. Bergsagel, D.E., Haas, R.H. and Messner, H.A. (1986) Interferon alpha-2 in treatment of chronic granulocytic leukemia.Sem. Oncol. 13, 29.

    CAS  Google Scholar 

  26. Kantarjian, H.M., Talpaz, M. and Keating, M.J. (1991) Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.Cancer 68, 1201.

    Article  PubMed  CAS  Google Scholar 

  27. Arcese, W., Mauro, F.R., Screnci, M., Alimena, G., Lo Coco, F., Iori, A.P., De Cuia, R.M., Fazi, P., Montefusco, E. and Mandelli, F. (1991) Interferon therapy for Ph-positive chronic myelogenous leukemia patients relapsing after T-cell depleted allogeneic bone-marrow transplantation.Eur. J. Cancer 27 (4), S28.

Download references

Author information

Authors and Affiliations

  1. Dipartimento di Scienze Biomediche ed, Oncologia Medica, Universita degli Studi Policlinico di Bari, Piazza G. Cesare II, 70124, Bari, Italy

    Vito M. Lauta

Authors
  1. Vito M. Lauta
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lauta, V.M. Interferon and chronic myelogenous leukaemia. Med Oncol 12, 41–46 (1995). https://doi.org/10.1007/BF01571407

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01571407

Keywords

Search

Navigation